The Progressive


A project of Common Dreams

For Immediate Release

+1 617 482 1211 (Toll-free 1-800-77-OXFAM)

Merck's Patent Pool Offer Not Enough for Global Access


In response to Merck's announcement that it has granted a license for its promising COVID-19 pill to the Medicines Patent Pool, Robbie Silverman, Oxfam America's Senior Managerfor Private Sector Engagement, made the following statement:

"Merck's move to license molnupiravir is welcome as it could indeed mean increased access to its promising COVID-19 drug in the poorest countries in the world. But this agreement still locks out access from a number of middle-income countries around the world, like large parts of Latin America, where millions of the world's poorest people live.

"A corporation should never decide who should live and who should die. Merck's move is yet another reminder that we need global solutions to a global pandemic. While this step will save lives, many more lives would be saved if Merck would issue a worldwide license for molnupiravir.

"Merck, as well as Pfizer and Moderna, must immediately share their life-saving technologies. It is high time for governments to step up by waiving intellectual property protections and mandating corporations share their technology that the public helped to fund. We need a comprehensive TRIPS waiver that covers vaccines, therapeutics, and diagnostics as the fastest way to saving the most lives and ending the pandemic as soon as possible."

Oxfam International is a global movement of people who are fighting inequality to end poverty and injustice. We are working across regions in about 70 countries, with thousands of partners, and allies, supporting communities to build better lives for themselves, grow resilience and protect lives and livelihoods also in times of crisis.